000285252 001__ 285252
000285252 005__ 20260217094354.0
000285252 0247_ $$2doi$$a10.1212/NXI.0000000000200555
000285252 0247_ $$2pmid$$apmid:41687038
000285252 037__ $$aDZNE-2026-00194
000285252 041__ $$aEnglish
000285252 082__ $$a610
000285252 1001_ $$00000-0002-5854-3759$$aWickel, Jonathan$$b0
000285252 245__ $$aReduced Hospital Incidence of Autoimmune Encephalitis During the COVID-19 Pandemic.
000285252 260__ $$aPhiladelphia, Pa.$$bWolters Kluwer$$c2026
000285252 3367_ $$2DRIVER$$aarticle
000285252 3367_ $$2DataCite$$aOutput Types/Journal article
000285252 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771317707_24909
000285252 3367_ $$2BibTeX$$aARTICLE
000285252 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285252 3367_ $$00$$2EndNote$$aJournal Article
000285252 520__ $$aThe aim of this study was to analyze changes in hospital incidence cases and disease severity of autoantibody-associated autoimmune encephalitis (AE) during the COVID-19 pandemic compared with the prepandemic period.A retrospective multicenter study analyzed data from 24 centers within the German Network for Research on Autoimmune Encephalitis (GENERATE). Patients with a new diagnosis of definite antibody-positive autoimmune encephalitis from 2017 to 2022 were included and divided into prepandemic (2017-2019) and pandemic (2020-2022) periods.Among 392 patients, 227 were diagnosed before and 165 during the pandemic (mean 9.5 vs 6.9 per site, p = 0.04). A reduction was observed in cases with antibodies to neuronal surface antigens (174 vs 122 cases; mean 7.3 vs 5.1 per site, p = 0.02), while cases with antibodies against intracellular antigens remained stable (p = 0.40). No differences were observed in disease severity, age, or sex distribution between periods.This study provides clinical data on antibody-positive AE before and during the COVID-19 pandemic. The findings do not support the hypothesis that SARS-CoV-2 infection triggers autoantibody-associated AE or increases disease severity.
000285252 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285252 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285252 650_7 $$2NLM Chemicals$$aAutoantibodies
000285252 650_2 $$2MeSH$$aHumans
000285252 650_2 $$2MeSH$$aCOVID-19: epidemiology
000285252 650_2 $$2MeSH$$aMale
000285252 650_2 $$2MeSH$$aFemale
000285252 650_2 $$2MeSH$$aMiddle Aged
000285252 650_2 $$2MeSH$$aRetrospective Studies
000285252 650_2 $$2MeSH$$aIncidence
000285252 650_2 $$2MeSH$$aEncephalitis: epidemiology
000285252 650_2 $$2MeSH$$aEncephalitis: immunology
000285252 650_2 $$2MeSH$$aAged
000285252 650_2 $$2MeSH$$aAdult
000285252 650_2 $$2MeSH$$aGermany: epidemiology
000285252 650_2 $$2MeSH$$aHashimoto Disease: epidemiology
000285252 650_2 $$2MeSH$$aHashimoto Disease: immunology
000285252 650_2 $$2MeSH$$aAutoantibodies: blood
000285252 650_2 $$2MeSH$$aSeverity of Illness Index
000285252 650_2 $$2MeSH$$aYoung Adult
000285252 650_2 $$2MeSH$$aAged, 80 and over
000285252 650_2 $$2MeSH$$aHospitalization: statistics & numerical data
000285252 7001_ $$aChung, Ha-Yeun$$b1
000285252 7001_ $$00000-0002-8609-5674$$aKonen, Franz Felix$$b2
000285252 7001_ $$0P:(DE-2719)9001490$$aRössling, Rosa$$b3
000285252 7001_ $$00000-0003-4196-022X$$aBertolini, Annikki$$b4
000285252 7001_ $$00009-0001-3748-1798$$aKraft, Andrea$$b5
000285252 7001_ $$00000-0003-3827-4245$$aSiebenbrodt, Kai$$b6
000285252 7001_ $$00000-0003-2179-3655$$aBittner, Stefan$$b7
000285252 7001_ $$aJuranek, Aleksandra$$b8
000285252 7001_ $$aBrokbals, Mosche$$b9
000285252 7001_ $$00000-0001-8901-5572$$aRäuber, Saskia$$b10
000285252 7001_ $$00009-0009-9880-1191$$aKlausewitz, Jaqueline$$b11
000285252 7001_ $$00000-0003-3057-6492$$aPfeffer, Lena K$$b12
000285252 7001_ $$aScherag, André$$b13
000285252 7001_ $$aMenge, Til$$b14
000285252 7001_ $$aFinke, Alexander$$b15
000285252 7001_ $$00000-0003-2883-0009$$aDoppler, Kathrin$$b16
000285252 7001_ $$aUrbanek, Christian$$b17
000285252 7001_ $$00000-0003-2225-8654$$aBien, Christian G$$b18
000285252 7001_ $$00000-0001-8121-3662$$aSeifert-Held, Thomas$$b19
000285252 7001_ $$00000-0002-6242-6010$$aHoffmann, Frank$$b20
000285252 7001_ $$00000-0002-5483-4276$$aWandinger, Klaus-Peter$$b21
000285252 7001_ $$00000-0001-9149-3071$$aTauber, Simone C$$b22
000285252 7001_ $$aSüße, Marie$$b23
000285252 7001_ $$00000-0002-9272-529X$$aLewerenz, Jan$$b24
000285252 7001_ $$00000-0002-6299-8238$$aMadlener, Marie$$b25
000285252 7001_ $$00000-0002-2180-5321$$aRostasy, Kevin$$b26
000285252 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b27
000285252 7001_ $$00000-0002-8077-481X$$aSühs, Kurt-Wolfram$$b28
000285252 7001_ $$00000-0001-7509-5268$$aKümpfel, Tania$$b29
000285252 7001_ $$00000-0001-6548-0410$$aThaler, Franziska S$$b30
000285252 7001_ $$00000-0002-8972-515X$$aLeypoldt, Frank$$b31
000285252 7001_ $$00000-0002-9859-581X$$aGeis, Christian$$b32
000285252 7001_ $$agroup, GENERATE study$$b33$$eCollaboration Author
000285252 773__ $$0PERI:(DE-600)2767740-0$$a10.1212/NXI.0000000000200555$$gVol. 13, no. 3, p. e200555$$n3$$pe200555$$tNeurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology$$v13$$x2332-7812$$y2026
000285252 8564_ $$uhttps://pub.dzne.de/record/285252/files/DZNE-2026-00194.pdf$$yRestricted
000285252 8564_ $$uhttps://pub.dzne.de/record/285252/files/DZNE-2026-00194.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285252 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001490$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285252 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000285252 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285252 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROL-NEUROIMMUNOL : 2022$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-13T18:57:06Z
000285252 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-13T18:57:06Z
000285252 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-02-13T18:57:06Z
000285252 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROL-NEUROIMMUNOL : 2022$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-06
000285252 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-06
000285252 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000285252 980__ $$ajournal
000285252 980__ $$aEDITORS
000285252 980__ $$aVDBINPRINT
000285252 980__ $$aI:(DE-2719)1810003
000285252 980__ $$aUNRESTRICTED